Story

Sinomed Subsidiary's Intracranial Stent System Receives EU MDR Certification

ENTHMSVIIDZHZH-TWJAKOHI
Aug 9, 20261 min read
Sinomed Subsidiary's Intracranial Stent System Receives EU MDR Certification
Text size
Background

Sinomed (688108.SH) announced that its holding subsidiary, Sinothromb Medical Technology Co., Ltd., has received certification for its self-expanding intracranial drug-eluting stent system. The approval allows the product to bear the CE mark, signifying compliance with the European Union's rigorous Medical Devices Regulation (MDR).

Key Regulatory Milestone

In a company filing, Sinomed confirmed that its independently developed COMETIU™ self-expanding intracranial drug-eluting stent system was certified by an EU notified body. The certification was granted under the Medical Devices Regulation (EU) 2017/745, a comprehensive and stringent framework for medical devices sold in the region.

This certification is a critical step for the company, as the CE mark is a prerequisite for commercializing medical products within the European Union and the European Economic Area. The approval validates the product's design, safety, and performance against high regulatory standards.

Market Access and Future Outlook

Sample IUX Markets – In-articleAd

While the CE mark grants access to the European market, Sinomed cautioned that significant commercial uncertainties remain. The company stated that the path to generating revenue involves several subsequent steps, including:

  • Completing post-market registration in individual EU member states.
  • Establishing effective sales and distribution channels.
  • Securing access to hospitals and obtaining reimbursement approvals from payers.

The company emphasized that market development is subject to "great uncertainty" and that future sales could be impacted by factors such as evolving EU regulations, the accumulation of clinical evidence, changes in treatment standards, and currency exchange rate fluctuations.

Sinomed noted it cannot yet predict the specific impact of the certification on its future financial performance. The company also clarified that this approval is applicable only within the EU and EEA and does not guarantee regulatory approval in other countries or regions.

Read next

More on Stocks
Back to latest news

LATEST